We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Platelet Function in Patients With an Acute Coronary Syndrome (ATLANTIS-ACS)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2013 by Jolanta Siller-Matula, Medical University of Vienna.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01992484
First Posted: November 25, 2013
Last Update Posted: November 25, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Jolanta Siller-Matula, Medical University of Vienna
  Purpose

The aims of the study are to:

  • explore whether platelet reactivity in patients treated wih novel platelet inhibitors is associated with clinical outcome
  • investigate whether a therapeutic window exist for novel platelet inhibitors
  • investigate the incidence of adverse events under treatment with novel platelet inhibitors in the real life clinical scenario
  • investigate the association between genetic polymorphisms, inflammation, platelet reactivity and clinical outcome
  • investigate synergistic effects between aspirin and novel platelet inhibitors

Condition
Acute Coronary Syndrome (ACS)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Association Between the Antiplatelet Drug Efficacy/Safety and Platelet Function in Patients Treated With Novel Platelet Inhibitors Due to an Acute Coronary Syndrome

Further study details as provided by Jolanta Siller-Matula, Medical University of Vienna:

Primary Outcome Measures:
  • Net clinical benefit. [ Time Frame: 1 year ]
    A composite of MACE and BARC=>2 bleedings.


Secondary Outcome Measures:
  • MACE and Major bleeding [ Time Frame: 1 year ]

    MACE: the composite of stent thrombosis, cardiac death and myocardial infarction.

    Major Bleeding: BARC =>2, TIMI major, GUSTO moderate-severe-life threatening.



Other Outcome Measures:
  • single endpoints of acute coronary syndrome, myocardial infarction, cardiac death, all-cause death, urgent vessel revascularization (PCI or CABG), stroke. [ Time Frame: 1 year ]

Estimated Enrollment: 1000
Study Start Date: August 2012
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients presenting with an acute coronary syndrome
Criteria

Inclusion Criteria:

  • Signed informed consent
  • Acute coronary syndrome at admission
  • Planned treatment with novel platelet inhibitors
  • Age >18

Exclusion Criteria:

* Participation in interventional trials

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01992484


Contacts
Contact: Jolanta M Siller-Matula, PD MD PhD 0043 1 404004614 jolanta.siller-matula@meduniwien.ac.at

Locations
Austria
Medical Univerity of Vienna, Department of Cardiology Recruiting
Vienna, Austria
Principal Investigator: Jolanta M Siller-Matula, PD MD PhD         
Principal Investigator: Georg Delle-Karth, MD         
Sponsors and Collaborators
Medical University of Vienna
  More Information

Responsible Party: Jolanta Siller-Matula, PD Dr.med. PhD, Medical University of Vienna
ClinicalTrials.gov Identifier: NCT01992484     History of Changes
Other Study ID Numbers: ATLANTIS-ACS
First Submitted: November 19, 2013
First Posted: November 25, 2013
Last Update Posted: November 25, 2013
Last Verified: November 2013

Keywords provided by Jolanta Siller-Matula, Medical University of Vienna:
platelets, Acute coronary Syndrome (ACS), prasugrel, ticagrelor, aspirin

Additional relevant MeSH terms:
Syndrome
Acute Coronary Syndrome
Disease
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases


To Top